Introduction
The expression of transfected genes by mammalian cells occurs after a number of cellular barriers have been overcome. Foreign DNA must be appropriately packaged such that it may be bound and taken up by the cell. Once internalized, the DNA must survive the endosomal/ lysosomal system which serves to hydrolyze macromolecules. Transfected DNA must be transported to the nucleus in order to be transcribed.
Receptor-mediated strategies have been adopted to introduce foreign DNA into cells, targeting specific cell types with specific ligands. For example, transferrin, 1 asialo-orosomucoid 2 and surfactant protein A, 3 when conjugated to poly-lysine chains, effect receptor-mediated uptake of DNA. The DNA is transported into the endosomal compartment of the cell. The fate of endocytosed polynucleotides is tied to the fate of the endosomal vesicles in which they reside. Fusion of primary endosomes with multivesicular bodies or lysosomes, containing endonucleases (eg DNase II), 4 leads to catabolism of the foreign DNA. The success of adenovirus-mediated gene transfer, in vitro has been attributed to the virus disrupting the endosomal membrane, facilitating the escape of DNA into the cytoplasmic compartment. 5, 6 Compared to adenoviruses, the lower efficiency of receptormediated transfection probably involves a slower rate of escape of DNA from the endosomal compartment. Still, the fact that receptor-mediated strategies are successful suggests that leakage of macromolecules from the endosomal system occurs. 2 If endocytosed DNA can be protected from degradation, the probability that it will reach the nucleus may increase. We hypothesize that transfection of cells, in the presence of specific DNase inhibitors might facilitate expression of the reporter gene.
To test this hypothesis, DNase inhibitors directed against the active sites of specific nucleases are required. Naturally occurring DNase inhibitors are produced by various strains of the antimycete Streptomyces sp. [7] [8] [9] When purified, these metabolites inhibit specific endonucleases. 9 These Streptomyces products may be useful to inhibit the cellular nucleases encountered by foreign DNA in the endosomal compartment.
In this study, we have used a Streptomyces sp. strain No. 560 metabolite, DMI-2, to facilitate the receptormediated transfection of lung adenocarcinoma (H441) cells by surfactant protein-A-poly-lysine conjugates. 3 DMI-2 is a polyketide metabolite, initially characterized for its inhibition of N 6 -methyladenosine-DNA methyltransferase (M.EcoR1).
10 DMI-2 was also shown to inhibit porcine spleen DNase II. Here, the utility of DMI-2 for enhancing transfection efficiency of receptor-mediated and receptor-independent methods was assessed.
Results
DMI-2 is a complex naphthacene derivative, soluble only in organic solvents. 10 It was anticipated that DMI-2 may be strongly lipophilic and potentially toxic to cells. At concentrations greater than 1 g/ml, DMI-2 is toxic to H441 cells cultured in media containing 10% fetal calf serum (Figure 1 ). The cells are less tolerant to DMI-2 when cultured with serum-free media and when cationic liposomes (2 g/3 ml complete media) are used. Decreased uptake of the vital dye neutral red is seen for cells exposed to 0.1 g/ml DMI-2 in serum-free media ( Figure 1 ) and for cells exposed to 0.5 g/ml DMI-2 in the presence of lipofectin (not shown). Cell toxicity was also shown by decreased total protein yield upon harvesting. To maintain cell viability, DMI-2 was used over the range 0.1-1.0 g/ml in the presence of 10% fetal calf serum.
DMI-2 enhances receptor-mediated transfection
We have previously reported that H441 cells can be transfected by a receptor-mediated process using pulmonary surfactant protein A conjugated to poly-lysine ([Lys] 21kD -SP-A). 3 When included in culture media during incubation with [Lys] 21kD -SP-A-pCPA-RSV complexes, DMI-2 enhances transfection efficiency approximately 10-fold ( Figure 2) .
To assess the utility of DMI-2 in other transfection systems, DMI-2 was included in transfection media containing lipofectin-DNA complexes. DMI-2 enhanced CAT expression (maximum enhancement, ×1.6) when the cationic liposomes were used ( Figure 3 ). DMI-2 did not enhance transfection with calcium phosphate precipitates ( Figure 4) .
Transferrin-poly-lysine conjugates have been used to transfect various cell types by a receptor-mediated pro- 
cess.
1 H441 cells were transfected using this 'transferrinfection' strategy and DMI-2 significantly enhanced reporter gene expression approximately nine-fold ( Figure 5 ).
The effect of DMI-2 on transfection using a plasmid containing a ␤-galactosidase reporter gene was also assessed. H441 cells, transfected with [Lys] 21kD -SP-ApCMV-␤-gal complexes, showed a higher number of transfected cells (enhanced X-gal staining) in the presence of DMI-2 ( Figure 6 ).
Inhibition of H441 acid nuclease activity by DMI-2 We tested whether acid nuclease activity present in H441 homogenates could be inhibited by DMI-2. Figure 7a shows a time-course of DNA digestion by a lysosomal subfraction from H441 cells. This acid nuclease activity is partially inhibited by DMI-2 ( Figure 7b ).
Methanolysis fragments of DMI-2 are inactive DMI-2 is an enol-keto tautomer of dutomycin, an antitumor antibiotic produced by Streptomyces sp. 1725. 11 We have adopted the methanolysis procedure described in the structural analysis of dutomycin, to fragment DMI-2 (see Materials and methods). The methanolysis products were assayed for their ability to inhibit porcine spleen DNase II ( Figure 8 ) and to enhance transfection of H441 cells using [Lys] 21kD -SP-A-pCPA-RSV complexes ( Figure  9 ). Neither the aqueous nor organic solvent soluble products retained the ability to inhibit DNase II or enhance gene transfer.
Discussion
The development of successful gene therapy strategies may depend on bypassing mechanisms by which cells protect themselves from the random incorporation of exogenous DNA sequences. Macromolecules are taken up from the extracellular environment and degraded by eukaryotic cells in the endosomal/lysosomal compartment, providing carbohydrate, amino acid and nucleic acid building blocks which the cell can utilize. At the same time, the degradation of DNA provides a significant barrier to the delivery of intact gene sequences, required for successful gene transfer. DNase II or 'acid nuclease' has been identified in the lysosomal fraction of porcine spleen. 4 The strict acid pH dependency of purified DNase II suggests that its principle site of action is within the endosomal/lysosomal pathway. DNase II, therefore, may represent the initial, intracellular, endonucleolytic barrier to foreign gene sequences.
In the present work, the expression of the reporter gene, chloramphenicol acetyltransferase, was enhanced by transfection of H441 cells in the presence of DMI-2. DMI-2 is a polyketide metabolite of Streptomyces sp. which inhibits porcine spleen DNase II.
10 DMI-2 is most effective when included in the media of cells being transfected by receptor-mediated complexes (transferrin-polylysine and SP-A-poly-lysine). Transfection efficiency can be increased by as much as 10-fold (Figures 2 and 5 ). These results are consistent with DMI-2 acting to protect the plasmid DNA in the endosomal/lysosomal compartment. We speculate that by slowing the breakdown of the intact gene sequence, DMI-2 may increase the probability that the DNA escapes from the lysosomal com- partment into the cell cytoplasm. DMI-2 does inhibit cellular acid nuclease activity in vitro (Figure 7 ).
DMI-2 has a more modest effect on transfection mediated by the cationic liposome preparation lipofectin (DOTMA:DOPE, 1:1) (Figure 3 ). Cationic liposomes are thought to deliver DNA via phagocytosis 12 and endosomal routing. 13 
Figure 6 Effect of DMI-2 on transfection using ␤-gal plasmid. [Lys] 21kD -SP-A was mixed with pCMV-␤-gal at a 100:1 (protein:DNA) molar ratio. Aliquots containing 1 picomole DNA were added to H441 cells and cultured for 18 h in the absence (open bar) or presence (cross-hatched bar) of 0.5 g/ml DMI-2. After removal of the transfection media, cells were cultured for 24 h and then fixed for X-gal staining. The number of blue cells was scored for each well. Data are representative of three experiments and are presented as mean ± s.d. (n = 4) with the control set equal to 1.0.

Figure 7 Inhibition of H441 acid nuclease by DMI-2. H441 cells were homogenized and the soluble fraction from the 15 000 g pellet obtained (see Materials and methods). Cell lysate (150 g/ml) protein was incubated at 37°C, pH 4.6, with calf thymus DNA (100 g/ml). At the indicated times, aliquots were neutralized and subjected to 1% agarose gel electrophoresis (Materials and methods). (a) Digestion under control conditions; (b) digestion in the presence of 40 g/ml DMI-2.
DMI-2 does not influence transfections using calcium phosphate coprecipitation (Figure 4 ). Loyter et al 18 demonstrated that calcium phosphate-DNA complexes are resistant to serum nucleases, and suggested that a more significant barrier to successful gene expression was the movement of DNA to the nucleus and its subsequent processing in the nucleus. Luthman and Magnusson 19 reported that treatment of cells with the lysosomotropic agent, chloroquine, enhanced expression of polyoma virus DNA sequences transfected via either DEAE-dextran or calcium phosphate methods. This finding suggests that calcium phosphate-DNA complexes are indeed exposed to hydrolytic attack in the endosomal-lysosomal compartment. Our finding that DMI-2 does not enhance calcium phosphate-mediated transfection suggests, however, that DNase II-like nucleases do not effectively hydrolyze calcium precipitated DNA.
DMI-2 consists of a substituted napthacene in ether linkage with two successive pyran rings and a terminal heptenoic acid ester. 10 DMI-2 is a tautomer of dutomycin 11 differing only in arrangement around the ninth car- bon of the napthacene ring. Acid methanolysis cleaved dutomycin at its ether linkages, 11 releasing the pyran rings from the naphthacene structure. Similar treatment of DMI-2 destroyed its ability to inhibit DNase II ( Figure  8 ) and the ability to enhance receptor-mediated transfection ( Figure 9 ). Our data suggest a correlation between inhibition of DNase II and enhancement of gene transfer and that intact DMI-2 is required for both activities.
As a polyketide product of Streptomyces secondary metabolism, DMI-2 is synthesized by the action of unique enzymatic complexes which also produce diverse clinical compounds such as the bactericidal agent erythromycin and the antitumor agent daunomycin. These naturally occurring compounds are synthesized from acetyl and malonyl thioesters by a polyketide synthase complex, along with ketoreductase, aromatase and cyclase activities. 20 Recently, the genetic localization of specific polyketide synthase enzymes has allowed manipulation of the Streptomyces genome to provide various combinations of enzyme activities. McDaniel et al 21 and Jacobsen et al 22 have demonstrated the production of novel polyketide products following such genetic programming. As the rules governing the concerted enzyme activities leading to polyketide synthesis are better understood, production of genetically designed compounds may be possible. Using DMI-2 and other Streptomyces compounds as a framework, the synthesis of even more potent and specific nuclease inhibitors may be achieved.
The present study was focused to determine the utility of DMI-2 with respiratory epithelial cells. DMI-2 or related compounds may be of potential use in other cell lines expressing DNase II-like activity.
In summary, DMI-2, an inhibitor of DNase II, enhances transfection of human pulmonary adenocarcinoma cells, being most effective when used with receptor-mediated vectors. Design of successful gene therapy protocols depends on improved understanding of the physical and chemical barriers working against the expression of foreign genes. Tissue and cellular nucleases are probably significant barriers to any method of gene transfer. The development of specific nuclease inhibitors, therefore, holds the potential for application in the clinical use of both viral and nonviral gene therapy vectors.
Materials and methods
Reagents 14 C-chloramphenicol was purchased from New England Nuclear (Boston, MA, USA). Leupeptin and Pepstatin A were obtained from Boehringer Mannheim (Indianapolis, IN, USA). Unspecified reagents were purchased from Sigma Chemical (St Louis, MO, USA).
Reporter plasmids
Transfection experiments were carried out using either plasmid DNA containing the bacterial chloramphenicol acetyltransferase gene (pCPA-RSV) 23 or plasmid DNA containing ␤-galactosidase (pCMV-␤gal). 24 Transfection agents Surfactant protein A was linked to poly-l-lysine ([Lys] 21kD -SP-A) as described. 3 Transferrin-poly-lysine was purchased from Serva (Heidelberg, Germany) and used according to the supplier's recommendations. Lipofectin (DOTMA:DOPE, 1:1) was purchased from Gibco BRL (Gaithersburg, MD, USA).
Cell culture and transfection
Pulmonary adenocarcinoma cells (H441) have characteristics of respiratory epithelial cells. Cells were maintained in six-well plastic dishes in RPMI-1640 media, containing penicillin/streptomycin/amphotericin and 10% fetal bovine serum (Gibco). Cells were transfected in a volume of 3 ml at 50-70% confluency. Transfection complexes (below) were added in volumes less than 200 l to the 3 ml culture media.
[Lys] 21kD -SP-A was mixed with plasmid at a 100:1 protein:DNA molar ratio and 1 or 2 picomoles of DNA added to each well as indicated. Transferrin-poly-lysine was resuspended at 25 units/ml and mixed with plasmid DNA such that approximately 2 units transferrin-poly-l-lysine and 1 picomole DNA were added to each well. Lipofectin was mixed with plasmid DNA such that 2 g lipid and 1 picomole DNA were added to each well. Plasmid DNA was precipitated with calcium phosphate and 1 picomole DNA added to each well.
The transfection complexes were incubated with the cells overnight (18-20 h) . Transfection media were then replaced with growth media and the cells grown for 2-3 days. Confluent cell monolayers were harvested and lysed in 0.25 m Tris-Cl, pH 7.8 by three freeze-thaw cycles followed by centrifugation (10 000 g, 10 min). Protein was determined by the bicinchoninic acid method 25 using BSA as a standard. CAT assays were performed on lysates normalized to protein concentration. Conversion of 14 C-chloramphenicol to acetylated forms was quantified using Phosphorlmager and ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA) as previously described. 23 Cells expressing the ␤-galactosidase reporter were assessed 24-48 h post-transfection by X-gal staining, following fixation with 2%-paraformaldehyde, 0.2% glutaraldehyde. 24 Addition of DMI-2 DMI-2 was purified from the post-mycelium culture filtrate of Streptomyces sp. strain No. 560 as described by Nagao et al. 10 DMI-2 has a molecular weight of 854 da and its structure was determined to be 4′′′R,6aR,10S,10a S-8-acetyl-6a,10a-dihydroxy-2-methoxy-12-methyl-10[4′-[3′′-hydroxy-3′′,5′′-dimethyl-4′′(Z-2′′′,4′′′-dimethyl-2′′′-heptenoyloxy) tetrahydropyran-1′′-yloxy]-5′-methyl-tetrahydropyran-1-′yloxy]-1,4,6,7,9-pentaoxo-1,4,6,6a,7,8,9,10,10a,11-decahydronaphthacene.
1 DMI-2 was dissolved in ethanol and added to cell cultures such that the ethanol concentration in the media did not exceed 0.1% (v/v).
Cellular toxicity was assessed via the active uptake of neutral red (adapted from Finter 26 ). Cells were exposed to varying doses of DMI-2 for 24 h. Neutral red (20 g/ml) was then added to the media and the cells incubated for 4 h. Cells were then washed three times with 2 ml cold PBS and extracted with 1 ml 50% EtOH, 13.5 mm sodium citrate pH 4.2. Cellular debris was removed by centrifugation (10 000 g for 5 min) and the absorbance at 540 mm measured.
Assay of H441 acid nuclease activity H441 cells were scraped into 10 mm Tris-HCl pH 7.4, 1 mm Na 2 EDTA, 1 mm PMSF 10 m Pepstatin A, 10 m Leupeptin (buffer A) containing 0.25 m sucrose. Cells were homogenized using a glass dounce homogenizer (30 strokes). Cell homogenates were centrifuged at 1000 g for 10 min using a JA-20 rotor (Beckman, Palo Alto, CA, USA) to pellet nuclei and cell debris. The post-nuclear supernatant was centrifuged at 15 000 g for 20 min. The resulting pellet was resuspended in buffer A (minus sucrose) and freeze thawed three times. Following microcentrifugation (10 000 g, 10 min), the supernatant was removed and tested for acid nuclease activity. Briefly, the H441 lysate (approximately 150 g/ml) was incubated at 37°C with calf thymus DNA (100 g/ml) in 0.1 n NaOAc protein pH 4.6, 0.1 m NaCl, 10 mm Na 2 EDTA. These conditions are identical to those used for assay of porcine spleen DNAse II (below).
Methanolysis of DMI-2
Fifty micrograms DMI-2 (1 mg/ml stock in ethanol) was first dried and then resuspended in 100 l methanol containing 5% (v/v) HCl. Samples were incubated for 1 h at room temperature. Two hundred microliters CHCl 3 was added and samples extracted with 150 l distilled H 2 O. Following vortexing and centrifugation (10 000 g, 3 min), the upper aqueous phase was removed. The organic phase was extracted twice more with 150 l aliquots of water. The aqueous extracts were pooled and both phases dried first by roto-evaporation using a water-jet and then by vacuum pump (Savant Instruments, Farmingdale, NY, USA). Dried fractions were dissolved in 50 l ethanol for DNase II inhibition (below) and transfection assays (above).
DNase II inhibition
Porcine spleen DNase II and calf thymus DNA were obtained from Sigma. All assays were 50 l initial volume in buffer containing 0.1 n sodium acetate, 0.1 n NaCl, 10 mm disodium EDTA, pH 4.6. DNA (100 g/ml) and enzyme (4 g/ml) were incubated at 37°C. At the indicated times, 8 l aliquots were removed and mixed with 3 l 1 m Tris-Cl, pH 8.8 containing bromophenol blue, xylene cyanol tracking dye. Samples were loaded directly on to a 1% agarose gel and electrophoresed using standard Tris/borate/EDTA buffer conditions. Degradation of DNA was assessed by ethidium bromide staining. Gels are presented as reverse images documented by UV transillumination using an IS-1000 Digital Imaging System (Alpha Innotech, San Leandro, CA USA).
